Help
RSS
API
Feed
Maltego
Contact
Domain > zermatt-consulting.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2018-07-08
66.96.130.28
(
ClassC
)
2024-09-12
107.152.41.187
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: openrestyDate: Thu, 12 Sep 2024 12:54:40 GMTContent-Type: text/htmlContent-Length: 166Connection: keep-aliveLocation: https://zermatt-consulting.com/ html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>openresty/center>/body>/html>
Port 443
HTTP/1.1 200 OKServer: openrestyDate: Thu, 12 Sep 2024 12:54:41 GMTContent-Type: text/html; charsetutf-8Content-Length: 20866Connection: keep-aliveX-Powered-By: ExpressCache-Control: public, max-age0ETag: W/5182-vYP3WuNkQJtCmx9OCwLW5T3P4nMVary: Accept-EncodingX-Served-By: zermatt-consulting.com !DOCTYPE html>html langen>head> meta charsetutf-8> meta nameviewport contentwidthdevice-width, initial-scale1> title>Consulting/ freelance of small biotechs and start-up in drug development, biologics, antibodies, bispecifics, drug discovery and development/title> link relstylesheet href/assets/built/screen.css?v31621f0540> meta namedescription contentYour Partner in Drug Development for Small Biotechs and Startups!> link relcanonical hrefhttps://zermatt-consulting.com/> meta namereferrer contentno-referrer-when-downgrade> meta propertyog:site_name contentZermatt Consulting> meta propertyog:type contentwebsite> meta propertyog:title contentZermatt Consulting> meta propertyog:description contentYour Partner in Drug Development for Small Biotechs and Startups!> meta propertyog:url contenthttps://zermatt-consulting.com/> meta propertyog:image contenthttps://zermatt-consulting.com/content/images/2024/02/linked-in-background-1.png> meta propertyarticle:publisher contenthttps://www.facebook.com/ghost> meta nametwitter:card contentsummary_large_image> meta nametwitter:title contentZermatt Consulting> meta nametwitter:description contentYour Partner in Drug Development for Small Biotechs and Startups!> meta nametwitter:url contenthttps://zermatt-consulting.com/> meta nametwitter:image contenthttps://zermatt-consulting.com/content/images/2024/02/linked-in-background-1.png> meta nametwitter:site content@ghost> meta propertyog:image:width content1200> meta propertyog:image:height content302> script typeapplication/ld+json>{ @context: https://schema.org, @type: WebSite, publisher: { @type: Organization, name: Zermatt Consulting, url: https://zermatt-consulting.com/, logo: { @type: ImageObject, url: https://zermatt-consulting.com/content/images/2024/02/Zermatt-logy-1.jpg } }, url: https://zermatt-consulting.com/, image: { @type: ImageObject, url: https://zermatt-consulting.com/content/images/2024/02/linked-in-background-1.png, width: 1200, height: 302 }, mainEntityOfPage: https://zermatt-consulting.com/, description: Your Partner in Drug Development for Small Biotechs and Startups!} /script> meta namegenerator contentGhost 5.89> link relalternate typeapplication/rss+xml titleZermatt Consulting hrefhttps://zermatt-consulting.com/rss/> script defer srchttps://cdn.jsdelivr.net/ghost/sodo-search@~1.1/umd/sodo-search.min.js data-keyaef157b8d3fc01ab9351faf6e8 data-styleshttps://cdn.jsdelivr.net/ghost/sodo-search@~1.1/umd/main.css data-sodo-searchhttps://zermatt-consulting.com/ crossoriginanonymous>/script> link hrefhttps://zermatt-consulting.com/webmentions/receive/ relwebmention> script defer src/public/cards.min.js?v31621f0540>/script>style>:root {--ghost-accent-color: #031a55;}/style> link relstylesheet typetext/css href/public/cards.min.css?v31621f0540> !-- Matomo -->script> var _paq window._paq window._paq || ; /* tracker methods like setCustomDimension should be called before trackPageView */ _paq.push(trackPageView); _paq.push(enableLinkTracking); (function() { var uhttps://stats.passward.se/; _paq.push(setTrackerUrl, u+matomo.php); _paq.push(setSiteId, 5); var ddocument, gd.createElement(script), sd.getElementsByTagName(script)0; g.asynctrue; g.srcu+matomo.js; s.parentNode.insertBefore(g,s); })();/script>!-- End Matomo Code -->/head>body classhome-template with-full-cover is-head-transparent is-head-left-logo>div classsite> header idgh-head classgh-head gh-outer> div classgh-head-inner> div classgh-head-brand> div classgh-head-brand-wrapper> a classgh-head-logo hrefhttps://zermatt-consulting.com> img srchttps://zermatt-consulting.com/content/images/2024/02/Zermatt-logy-1.jpg altZermatt Consulting> /a> /div> button classgh-search gh-icon-btn aria-labelSearch this site data-ghost-search>svg xmlnshttp://www.w3.org/2000/svg fillnone viewBox0 0 24 24 strokecurrentColor stroke-width2 width20 height20>path stroke-linecapround stroke-linejoinround dM21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z>/path>/svg>/button> button classgh-burger>/button> /div> nav classgh-head-menu> ul classnav> li classnav-home nav-current>a hrefhttps://zermatt-consulting.com/>Home/a>/li> li classnav-services>a hrefhttps://zermatt-consulting.com/services/>Services/a>/li> li classnav-about>a hrefhttps://zermatt-consulting.com/about/>About/a>/li> li classnav-resources>a hrefhttps://zermatt-consulting.com/Resources/>Resources/a>/li>/ul> /nav> div classgh-head-actions> button classgh-search gh-icon-btn aria-labelSearch this site data-ghost-search>svg xmlnshttp://www.w3.org/2000/svg fillnone viewBox0 0 24 24 strokecurrentColor stroke-width2 width20 height20>path stroke-linecapround stroke-linejoinround dM21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z>/path>/svg>/button> /div> /div> /header> div classcover image-loading half gh-outer> img classcover-image u-object-fit srchttps://zermatt-consulting.com/content/images/2024/02/linked-in-background-1.png altZermatt Consulting> div classcover-content> div classcover-description> Your Partner in Drug Development for Small Biotechs and Startups! /div> /div> button classbutton-icon cover-arrow> svg xmlnshttp://www.w3.org/2000/svg width192 height192 fillcurrentColor viewBox0 0 256 256 classicon> rect width256 height256 fillnone>/rect>polyline points208 96 128 176 48 96 fillnone strokecurrentColor stroke-linecapround stroke-linejoinround stroke-width24>/polyline>/svg> /button>/div> div classsite-content> main classsite-main> header classfeed-header gh-canvas> div classfeed-header-wrapper> h2 classfeed-header-title>Latest/h2> /div> /header> div classpost-feed expanded gh-feed gh-canvas> article classfeed post data-monthSeptember 2024> div classfeed-calendar> div classfeed-calendar-month> Sep /div> div classfeed-calendar-day> 10 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcset/content/images/size/w400/2024/09/first-data.jpg 400w,/content/images/size/w750/2024/09/first-data.jpg 750w,/content/images/size/w960/2024/09/first-data.jpg 960w,/content/images/size/w1140/2024/09/first-data.jpg 1140w sizes(min-width: 576px) 160px, 90vw src/content/images/size/w750/2024/09/first-data.jpg altFirst indication of PBA-0405 activity in patient settings loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>First indication of PBA-0405 activity in patient settings/h2> div classfeed-excerpt>Pure Biologics released first biomarker data obtained in Phase O clinical study in Head and Neck patients receiving intra-tumoral injection/div> div classfeed-right> time classfeed-date datetime2024-09-10> Sep 10, 2024 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-length> 1 min read /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/first-indication-of-pba-0405-activity-in-patient-settings/ aria-labelFirst indication of PBA-0405 activity in patient settings>/a>/article> article classfeed post data-monthJuly 2024> div classfeed-calendar> div classfeed-calendar-month> Jul /div> div classfeed-calendar-day> 16 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcset/content/images/size/w400/2024/08/1721225999283.jpg 400w,/content/images/size/w750/2024/08/1721225999283.jpg 750w,/content/images/size/w960/2024/08/1721225999283.jpg 960w,/content/images/size/w1140/2024/08/1721225999283.jpg 1140w sizes(min-width: 576px) 160px, 90vw src/content/images/size/w750/2024/08/1721225999283.jpg altPBA-0111 received "Study may proceed" letter from FDA loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>PBA-0111 received "Study may proceed" letter from FDA/h2> div classfeed-excerpt>Pure Biologics took another significant step forward by receiving a "study may proceed" letter from the US Food/div> div classfeed-right> time classfeed-date datetime2024-07-16> Jul 16, 2024 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-length> 1 min read /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/pba-0111-received-study-may-proceed-letter-from-fda/ aria-labelPBA-0111 received "Study may proceed" letter from FDA>/a>/article> article classfeed post data-monthJuly 2024> div classfeed-calendar> div classfeed-calendar-month> Jul /div> div classfeed-calendar-day> 15 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcset/content/images/size/w400/2024/08/1721287408187.jpg 400w,/content/images/size/w750/2024/08/1721287408187.jpg 750w,/content/images/size/w960/2024/08/1721287408187.jpg 960w,/content/images/size/w1140/2024/08/1721287408187.jpg 1140w sizes(min-width: 576px) 160px, 90vw src/content/images/size/w750/2024/08/1721287408187.jpg altFirst patient dosed with PBA-0405 loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>First patient dosed with PBA-0405/h2> div classfeed-excerpt>Pure Biologics announced on July 15, 2024 the dosing of the first patient was with the candidate PBA-0405 in a/div> div classfeed-right> time classfeed-date datetime2024-07-15> Jul 15, 2024 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-length> 1 min read /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/first-patient-dosed-with-pba-0405/ aria-labelFirst patient dosed with PBA-0405>/a>/article> article classfeed post tag-news data-monthFebruary 2024> div classfeed-calendar> div classfeed-calendar-month> Feb /div> div classfeed-calendar-day> 25 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcsethttps://static.ghost.org/v4.0.0/images/feature-image.jpg 400w,https://static.ghost.org/v4.0.0/images/feature-image.jpg 750w,https://static.ghost.org/v4.0.0/images/feature-image.jpg 960w,https://static.ghost.org/v4.0.0/images/feature-image.jpg 1140w sizes(min-width: 576px) 160px, 90vw srchttps://static.ghost.org/v4.0.0/images/feature-image.jpg altComing more soon loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>Coming more soon/h2> div classfeed-excerpt>This is Zermatt Consulting, a brand new site that's just getting started. Things will be up and running/div> div classfeed-right> time classfeed-date datetime2024-02-25> Feb 25, 2024 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/coming-soon/ aria-labelComing more soon>/a>/article> article classfeed post data-monthDecember 2023> div classfeed-calendar> div classfeed-calendar-month> Dec /div> div classfeed-calendar-day> 20 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcset/content/images/size/w400/2024/02/eIND.jpg 400w,/content/images/size/w750/2024/02/eIND.jpg 750w,/content/images/size/w960/2024/02/eIND.jpg 960w,/content/images/size/w1140/2024/02/eIND.jpg 1140w sizes(min-width: 576px) 160px, 90vw src/content/images/size/w750/2024/02/eIND.jpg altPBA-0405 receives FDA "study may proceed" loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>PBA-0405 receives FDA "study may proceed"/h2> div classfeed-excerpt>We are proud to announce that Zermatt Consulting has played a significant role in Pure Biologics approval receival from the/div> div classfeed-right> time classfeed-date datetime2023-12-20> Dec 20, 2023 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-length> 1 min read /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/pba-0405-receives-study-may-proceed/ aria-labelPBA-0405 receives FDA "study may proceed">/a>/article> article classfeed post data-monthDecember 2023> div classfeed-calendar> div classfeed-calendar-month> Dec /div> div classfeed-calendar-day> 19 /div> /div> div classfeed-image u-placeholder rectangle> img classu-object-fit srcset/content/images/size/w400/2024/02/christmas.jpg 400w,/content/images/size/w750/2024/02/christmas.jpg 750w,/content/images/size/w960/2024/02/christmas.jpg 960w,/content/images/size/w1140/2024/02/christmas.jpg 1140w sizes(min-width: 576px) 160px, 90vw src/content/images/size/w750/2024/02/christmas.jpg altWarm holiday wishes from Zermatt Consulting! loadinglazy > /div> div classfeed-wrapper> h2 classfeed-title>Warm holiday wishes from Zermatt Consulting!/h2> div classfeed-excerpt>The year 2023 has been very busy and productive. Zermatt consulting was part of an exiting journey from drug discovery,/div> div classfeed-right> time classfeed-date datetime2023-12-19> Dec 19, 2023 /time> div classfeed-visibility feed-visibility-public> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM16 23.027L24.24 28l-2.187-9.373 7.28-6.307-9.587-.827-3.747-8.827-3.747 8.827-9.587.827 7.267 6.307L7.759 28l8.24-4.973z>/path>/svg> /div> div classfeed-icon> svg classicon xmlnshttp://www.w3.org/2000/svg viewBox0 0 32 32> path dM11.453 22.107L17.56 16l-6.107-6.12L13.333 8l8 8-8 8-1.88-1.893z>/path>/svg> /div> /div> /div> a classu-permalink href/untitled/ aria-labelWarm holiday wishes from Zermatt Consulting!>/a>/article> /div> nav classload-more> button classbutton button-secondary gh-loadmore>Load more/button>/nav>/main> /div> footer classgh-foot gh-outer> div classgh-foot-inner gh-inner> div classgh-copyright> Zermatt Consulting © 2024 /div> nav classgh-foot-menu> ul classnav> li classnav-services>a hrefhttps://zermatt-consulting.com/services/>Services/a>/li> li classnav-about>a hrefhttps://zermatt-consulting.com/about/>About/a>/li>/ul> /nav> div classgh-powered-by> a hrefhttps://ghost.org/ target_blank relnoopener>Powered by Ghost/a> /div> /div> /footer>/div>script> if (document.body.classList.contains(with-full-cover) && (/Android|webOS|iPhone|iPad|iPod|BlackBerry/i.test(navigator.platform))) { document.getElementsByClassName(cover)0.style.height window.innerHeight + px; }/script>script src/assets/built/main.min.js?v31621f0540>/script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]